home
about us
pipeline
investors
research
news
events
careers
sitemap
contact
© 2008 BionorImmuno, Inc. All rights Reserved
2010
2009
2008
2007
2006
2005
2004
2003
Date Title 23/08/10
Independent research report on Bionor published in Thomson Reuters' "Current Opinion in Investigational Drugs"
22/07/10
"Vacc-4x Shows Response Seven Years after Inoculation"
21/06/10
"Bionor Immuno's re-vaccination study accepted as a poster at the XVIII International AIDS conference"
19/05/10
"Nutri Pharma ASA to change name to Bionor Pharma ASA"
15/03/10
"Vacc-C5 to be prepared for phase I/II clinical trial."
26/02/10
"Bionor Immuno AS has appointed a new board of directors with Mr Thorleif Krarup as chairman"
12/02/10
"Nutri Pharma ASA has acquired 98,3% of the shares in Bionor Immuno AS."
12/01/10
"Nutri Pharma ASA has launched a voluntary offer for Bionor Immuno AS."
NEWS 2010
ABOUT US
PIPELINE
RESEARCH
NEWS
SITEMAP
CONTACT US
EVENTS
CAREERS
HOME
INVESTORS
Bionor Immuno AS, a subsidary of Bionor Pharma ASA was established on July 14th 2000 as a spin off from the R&D on immune based therapies that until then had been performed by its sister company, Bionor AS. Both companies are located at the Telemark Biomedical Centre, Skien, Norway together with two of its development partners AS Telelab and Mericon AS.